Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV zanamivir pharmacokinetics and safety in neonates and infants with complicated influenza
2019-001588-63Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanamivir in influenza, sponsored by GSK. Primary endpoint: Area under the serum concentration-time curve. Started Aug 2020; status: terminated.
02
Drugs
zanamivir
03
Conditions
influenza
Beyond the preview
Go deeper on 2019-001588-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001588-63.